header logo image


Page 1,035«..1020..1,0341,0351,0361,037..1,0401,050..»

Solid Advances in Tumor Microenvironment Research – Genetic Engineering & Biotechnology News

April 10th, 2017 7:43 pm

Immune Cells Gone Wrong

In a talk provocatively titled MacrophagesEvildoers in Cancer, Jeffrey W. Pollard, Ph.D., of the MRC Centre for Reproductive Health at the University of Edinburgh, described how tumor evolution to malignancy requires manipulation of its tissue microenvironment. This is particularly true, he noted, for the immune infiltrate that is biased away from responding to the tumor to effect control and instead actively promotes progression.

The tumor immune response thus downregulates cytotoxic T-cell responses and promotes tissue repair and morphogenic activities of the infiltrating immune cells, Dr. Pollard indicated in his abstract. Thus, the environment tends to be dominated by innate immune cells, particularly macrophages and neutrophils, while cytotoxic T cells are often excluded.

Dr. Pollards group has been interested in macrophages. In many different mouse models of cancer, these immune cells have been shown to promote tumor progression and enhance metastasis. In fact, he emphasized, macrophages appear to be involved in every step of tumor progression. They stimulate tumor initiation, enhance angiogenesis, promote tumor cell migration and intravasation, increase stem cell viability, suppress immune responses, and, at the metastatic site, promote extravasation and persistent growth.

Macrophage ablation, Dr. Pollards team has observed, results in inhibition of tumor progression and metastasis. It has also found that macrophage biologic activities are induced through a dynamic interplay with tumor cells that often involves reciprocal signaling.

Dr. Pollards group has been particularly interested in the involvement of macrophages in enhancing metastasis, since it is metastatic disease that is responsible for most cancer deaths. The group, stated Dr. Pollard, has demonstrated a chemokine-signaling cascade that results in the recruitment of the progenitor monocytes and their retention in the tissue. This results, he continued, in differentiation of what we have termed metastasis-associated macrophages (MAMs).

MAMs confer survival signals and growth advantage to metastatic cells, elaborated Dr. Pollard. The MAMs, in turn, respond to local signals to upregulate an inflammatory gene signature through the tyrosine kinase transmembrane receptors, vascular endothelial growth factor receptor 1 (VEGFR1 or FLT1) and colony stimulating factor 1 receptor (CSF1R). Furthermore, monocytes appear to be preadapted by the primary tumor to promote metastasis by the generation of preferred sites known as premetastatic niches. Thus, understanding monocyte biology, the mechanisms of their recruitment, and differentiation is of central importance to the fundamental appreciation of the role of macrophages in the tumor.

Read more here:
Solid Advances in Tumor Microenvironment Research - Genetic Engineering & Biotechnology News

Read More...

Mesoblast takes off as cell therapy for heart failure passes interim test – FierceBiotech

April 10th, 2017 7:43 pm

At the halfway point, a phase 3 trial of Mesoblast's off-the-shelf cell therapy for chronic heart failure is on track and should continue to completion, say advisers.

Shares in the Australian biotech hit a 12-month high on the update from the trial, which came after it enrolled 270 out of a planned total of 600 patients with moderate CHF andcruciallyrevealed no safety issues with Mesoblast's MPC-150-IM candidate.

The trial is still blinded so there is now way to tell if the therapy is having an effect, but it's a case of so far, so good, as the biotech looks ahead to completing the study next year.

The trial is seeing whether delivery of mesenchymal precursor cells (MPCs) via a catheter into the left ventricular heart muscle, to see if it can reduce non-fatal heart failure-related major adverse cardiac events (HF-MACE), such as death, needing a pacemaker implanted or undergoing a heart transplant.

Last year, Israeli drugmaker Teva returned rights to MPC-150-IM to Mesoblast, which it had inherited through its takeover of Cephalon. Mesoblast however decided to go it alone, a decision helped by a recent $40 million placement intended to help bring the CHF trial to fruition.

Analyst John Savin at Edison said in a recent note that the biotech may not have to wait for its own trial to complete before filing for U.S. approval. That could happen before the end of the year if a National Institutes of Health-sponsored trial of the therapy in end-stage heart failure patients hits the target.

The 159-patient NIH study is expected to complete enrolment in the first half andwith luckcould report top-line data before year-end, according to Savin. He reckons that could "lead to an application for accelerated approval" under the U.S. 21st Century Cures Act, which provides a speedy route to market for regenerative medicines.

"Passing this interim futility analysis for MPC-150-IM is an important milestone for Mesoblast and our cardiovascular disease program," commented CEO Silviu Itescu. "This validates our strategy and our prioritization of this valuable program." Analysts at Credit Suisse have previously suggested that that drug could be worth $4.1 billion in peak annual sales.

Mesoblast is not the only biotech looking at a stem cell approach to cardiovascular diseases. BioCardia is developing CardiAMP for CHF, reporting positive data from small phase 2 trial last year, while CardioCell presented mixed results on its candidate at the 2016 ESC Congress in Rome, and Celyad's C-Cure product failed to meet its objectives in its phase 3 CHART trial. Meanwhile, Belgium's TiGenix said recently its acute myocardial infarction therapy AlloCSC-01 hit its targets in a phase 1/2 trial.

The Australian biotech claimed an FDA green light to start trials of an MPC therapy given alongside corrective heart surgery for children with hypoplastic left heart syndrome (HLHS).

It's also in the build-up to a decision by option partner Mallinckrodt on its phase 3 MPC for chronic low back paindue in or before Septemberand a graft-versus-host disease (GVHD) candidate that should see pivotal results before year-end.

Read this article:
Mesoblast takes off as cell therapy for heart failure passes interim test - FierceBiotech

Read More...

Earnings Preview: Biotechnology Looks Healthy – Barron’s

April 10th, 2017 7:42 pm

Barron's
Earnings Preview: Biotechnology Looks Healthy
Barron's
The iShares Nasdaq Biotechnology (IBB) has climbed 0.34%. Meanwhile the SPDR S&P Biotech ETF (XBI) has declined 0.21%. IBB could be benefiting from having a wider swath of companies, in addition to the fact that the average market cap of its index ...

and more »

More:
Earnings Preview: Biotechnology Looks Healthy - Barron's

Read More...

President of Senegal bucks anti-biotechnology pressure: ‘I am for the use of GMOs’ – Genetic Literacy Project

April 10th, 2017 7:42 pm

President Macky Sall of Senegal has thrown his weight behind the adoption of agricultural biotechnology in the country.

.

President Sall made it clear that he supported the implementation of biotechnology in Senegal provided necessary measures to minimise risks were taken.

Macky Sall

I must say very clearly that I am for the use of GMOs based on the precautions taken and based on a dynamic regulation, otherwise we would be against progress. We must decide and step forward. We need to move forward because we have food security imperatives.

It is undeniable that GMOs can help meet current challenges, such as food insecurity, public health issues, natural resource conservation and climate change, he stressed.

We need serious thought to develop a strategy to maximise the use of GMOs, while mitigating the risks associated with them. That is why it is necessary to strengthen the National Biosafety Authority and to have an appropriate legal system combined with an efficient information system based on objective scientific values to assess the cost/benefit/risks ratio, he further stressed.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:GMOs: Senegal supports adoption of agric biotech

For more background on the Genetic Literacy Project, read GLP on Wikipedia

Continued here:
President of Senegal bucks anti-biotechnology pressure: 'I am for the use of GMOs' - Genetic Literacy Project

Read More...

Obesity May Make Rheumatoid Arthritis Tough to Spot – WebMD

April 10th, 2017 7:41 pm

By Robert Preidt

HealthDay Reporter

MONDAY, April 10, 2017 (HealthDay News) -- Blood tests to diagnose and monitor rheumatoid arthritis may be thrown off by obesity in women, a new study suggests.

"Physicians might assume that high levels of inflammation mean that a patient has rheumatoid arthritis or that their rheumatoid arthritis requires more treatment, when in fact a mild increase in levels of inflammation could be due to obesity instead," explained study author Dr. Michael George, who's with the University of Pennsylvania Health System in Philadelphia.

Blood tests for C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) can help physicians check the severity of inflammation in rheumatoid arthritis patients, the researchers said.

Previous studies have suggested that obese women may normally have higher CRP and ESR levels. So, the authors of this study decided to take a closer look at the issue.

The study included information from more than 2,100 people with rheumatoid arthritis. The researchers then compared that information to data from the general population.

A higher body mass index (BMI -- an estimate of body fat based on weight and height) was associated with greater CRP in women with rheumatoid arthritis and women in the general population, especially in severely obese women. There was also a modest association between obesity and ESR.

Conversely, in men with rheumatoid arthritis, a lower BMI was associated with greater CRP and ESR.

The findings may help improve understanding of the link between weight and inflammation. It may also help doctors learn more about how this relationship differs between women and men, the study authors added.

The findings were published April 10 in the journal Arthritis Care & Research.

"Our results suggest that obesity may lead to increased levels of CRP and ESR in women with rheumatoid arthritis," George said in a journal news release.

"The increase in these levels of inflammation was not because rheumatoid arthritis was worse in these women," he said.

"In fact, we found that obesity leads to very similar increases in these lab tests even in women without rheumatoid arthritis," he added.

Doctors should be careful when interpreting the results of these lab tests since both rheumatoid arthritis and obesity can contribute to inflammation levels, George said.

WebMD News from HealthDay

SOURCE: Arthritis Care & Research, news release, April 10, 2017

Continued here:
Obesity May Make Rheumatoid Arthritis Tough to Spot - WebMD

Read More...

In familiar routine, ICER finds rheumatoid arthritis drugs overpriced … – BioPharma Dive

April 10th, 2017 7:41 pm

Dive Brief:

Many of the world's top drugs are targeted immune modulators (TIMs) indicated for treatment of rheumatoid arthritis.

This broad class of newer drugs substantially improved upon older disease-modifying anti-rheumatic drugs (DMARDs)such as methotrexate, helping many patients better control disease symptoms and extending survival. Even so, the broad market opportunity rheumatoid arthritis is estimated to affect between 1.3 and 1.8 million Americans continues to draw drugmaker interest, with potential new entrants from Regeneron(sarilumab) and Eli Lilly (baricitinib) currently undergoing regulatory review.

In its report, ICERconsidered 11 TIMs, including those two experimental agents from Regeneron and Eli Lilly.

"Our analyses indicate that all the TIMsof interest in this evaluation substantially improved health outcomes compared to conventional DMARDs alone," ICER concluded in its report.

"However, their additional cost led to cost-effectiveness estimates that were well above commonly cited thresholds for cost effectiveness, and the discounts required to achieve these thresholds are greater than estimated current discounts from WAC."

In its conclusion,ICER suggested policy makers "may need to consider regulatory intervention" in order to ensure drug prices for TIMs don't continue to increase as they have in recent years.

Drugmakersfrom across the industry have sparred with ICER over its evaluations, frequently accusing the organization of failing to incorporate patient perspectives and attacking its use of benchmarks like quality-adjusted life years (QALY).

Amgen, for example,has criticized ICER'smethodology, arguing its model "relies too heavily" on short-term trial data, thereby overestimating the effect of conventional DMARDtherapy.

"The ICERrheumatoid arthritis report fails to fully capture the value of targeted immune modulators by using an outdated, one-size-fits-all economic model," the company said in an emailed statement.

ICERhas responded forcefully in the past, publishing a point-by-point rebuttalof often-used criticisms last August. Additionally, the group recently revised its value-assessment framework, drawing on feedback and comments from payers, patient groups and the industry. This most recent report largely relied on the older framework while reviews that begin in 2017 will use the newer one.

Previous reports from ICERon treatments for hepatitis C,high cholesterol and multiple myelomahave found many top-selling brands to be overpriced compared to cost-effectiveness benchmarks.

Analyses such as these provide evidence-based fodder that payers and other stakeholders have seized upon to push back against the industry on pricing. Given the well-entrenched position of many TIMs in the market, the direct impact of ICER's report in the existing rheumatoid arthritis market may be more limited.

But its conclusions regarding Actemra and sarilumab could impact payer consideration of those drugs, or guide Regeneronand Eli Lilly's pricing calculus for their respective experimental drugs, if approved by the FDA.

Read the original here:
In familiar routine, ICER finds rheumatoid arthritis drugs overpriced ... - BioPharma Dive

Read More...

Stem Cell Therapy Market – Worldwide Industry Scope, Size …

April 10th, 2017 7:41 pm

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

The study presents reliable qualitative and quantitative insights into:

The regional analysis covers:

The vast market research data included in the study is the result of extensive primary and secondary research activities. Surveys, personal interviews, and inputs from industry experts form the crux of primary research activities and data collected from trade journals, industry databases, and reputable paid sources form the basis of secondary research. The report also includes a detailed qualitative and quantitative analysis of the market, with the help of information collected from market participants operating across key sectors of the market value chain. A separate analysis of macro- and micro-economic aspects, regulations, and trends influencing the overall development of the market is also included in the report.

Highlights of the report:

Note: Immense care has been taken to present data with the highest levels of accuracy in all TMRResearch reports. Nevertheless, recent developments related to market/vendor landscape may take time to reflect in the analysis.

Read more:
Stem Cell Therapy Market - Worldwide Industry Scope, Size ...

Read More...

Stem Cell Therapy | Stem Cell Treatments | Idaho Falls …

April 10th, 2017 7:41 pm

Chronic pain is a problem that sadly affects most people within their lifetime. There are patients who fall into the category of not responding to noninvasive therapies but they decline or are not candidates for joint or spine surgery. Some clinicians are turning to autologous stem cell therapy and they are seeing benefits.

Evidence of the effectiveness of the pain relief seen by the therapy have been reported to be at least 50% in relative consistency in some correlational studies, meaning the treatments may be working fairly well for a number of patients. A significant number of results have been seen in patients as much as 3 years after the procedure is performed, meaning that recuperation is highly likely for all types of pain and injuries.

Promising application of stem cell therapy resides within the treatment of degenerative disc disorder, which affects millions of people within the United States. In 2015, Pettine, Murphy, Suzuki et al. found that by using autologous stem cells to treat discogenic low back pain, they were able to improve pain scores in 21 of 26 patients within their study. Rehydration of the discs in eight of twenty patients according to MRI in conjunction with sustained pain relief through 12 months represents promise for the use of this regenerative medicine approach (Pettine, Murphy, Suzuki et al, 2014). Results such as these are promising and are currently encouraging larger clinical trials in order to generalize results across a very extensive breadth of patients.

Teton Spine and Sports Pain Center utilizes stem cells for the treatment of:

Repeat treatment can be initiated after 6 months for optimal results for patients with severe symptoms.

Stem cells have been clinically and scientifically proven to effectively treat chronic and acute pain. Stem cells are the bodys master cells. They are undifferentiated cells that have the ability to transform into a variety of different cells, replace dying cells, and regenerate damaged tissue. Stem cells are derived from your own bodys bone marrow or fat deposit (adipose).

An alternative method for regenerative medicine is through allograft tissues (from a purified amniotic source). These tissues have a high concentration of collagens, structural proteins and growth factors that support healing. This immune-privileged tissue can have some advantages over other regenerative therapies. Speak with our physician about which regenerative medicine technique would be right for you and your injury.

Stem cell therapy is a very simple and safe outpatient procedure that is performed by a qualified physician. Its easy as 1, 2, 3!

Removal of bone marrow or fat tissue. If you choose to use amniotic stem cells, half the battle is already over.

Once a sample of your bone marrow or fat tissue has been obtained, the cells are isolated with a specialized centrifuge. If you decide to use amniotic stem cells, they are delivered to the doctors office ready for injection.

The stem cells are then carefully injected into the site where the injury exists and the healing and regeneration begins!

Two advantages of a stem cell injection over surgery are:

Most patients find themselves back in their daily routine the day after the procedure. Healing gradually happens over the course of 2-6 weeks and can continue for up to 12+ months.

If you havent already learned all the wonderful benefits of stem cell therapy, here they are listed out for you:

Stem cell therapy procedures can treat the following conditions (but not limited to):

If you don't see your condition, please contact us. You may still be a candidate for stem cell therapy.

Stem cells are harvested and concentrated from amniotic fluid, bone marrow, or fat to be re-injected directly into damaged or degenerated tissues. This procedure is performed on the same day for the patients convenience and stem cells are minimally altered so as to advance the healing process for each patient. Since cells are obtained from the patient and returned to the patient within a single surgical procedure in most procedures, there are no issues with immune rejection or increased risk of infection.

Continue reading here:
Stem Cell Therapy | Stem Cell Treatments | Idaho Falls ...

Read More...

Cell Therapy 2.0: Reprogramming the Brain’s Own Cells for Parkinson’s Treatment – Scientific American

April 10th, 2017 7:41 pm

For the past five decades pharmaceutical drugs like levodopa have been the gold standard for treating Parkinsons disease. These medications alleviate motor symptoms of the disease, but none of them can cure it. Patients with Parkinsons continue to lose dopamine neurons critical to the motor control centers of the brain. Eventually the drugs become ineffective and patients tremors get worse. They experience a loss of balance and a debilitating stiffness takes over their legs.

To replace the lost dopamine neurons, scientists have begun investigating stem cell therapy as a potential treatment or even a cure. But embryonic cells and adult stem cells have proved difficult to harness and transplant into the brain.

Now a study from the Karolinska Institute in Stockholm shows it is possible to coax the brains own astrocytescells that typically support and nurture neuronsinto producing a new generation of dopamine neurons. The reprogrammed cells display several of the properties and functions of native dopamine neurons and could alter the course of Parkinsons, according to the researchers. You can directly reprogram a cell that is already inside the brain and change the function in such a way that you can improve neurological symptoms, says senior author Ernest Arenas, a professor of medical biochemistry at Karolinska. Previously, scientists had to nudge specialized cells like neurons into becoming pluripotent cells before they could develop a different kind of specialized cell, he says. It was like having to erase all the written instructions for how a cell should develop and what job it should do and then rewriting them all over again. But Arenas and his team found a way to convert the instructions into a different set of commands without erasing them.

By adding a cocktail of three genes and a small RNA moleculeNEUROD1, ASCL1, LMX1A and miR-218, respectivelythe researchers forced astrocytes to transform directly into dopamine neurons. In culture, once human astrocytes were successfully reprogrammed this way, they looked and acted just like normal midbrain dopamine neurons. The reprogrammed cells grew axons, the long fibers that make connections with other neurons, fired electrical signals and released dopamine.

In mice, researchers first destroyed dopamine neurons in one part of the brain to produce a model of Parkinsons. Then they injected the cocktail of genes into the brain and observed the mice as they walked on a tiny treadmill. Within five weeks the mice began to walk straighter, their movements were more coordinated and their posture was improved.

The results, which were published in Nature Biotechnology today, open the door to a novel therapeutic approach for Parkinsons. Directly converting astrocytes already present in patients brains could eliminate the need to search for donor cells as well as avoid the risk of immunosuppression of transplanted cells. The treatments would also produce proteins involved in normal cellular processes and may therefore be less likely to cause side effects compared with current drugs. This is like stem cell 2.0. Its the next-generation approach to stem cell treatments and regenerative medicine, says James Beck, vice president of scientific affairs, for the nonprofit Parkinsons Disease Foundation who was not involved with the research. An estimated one million Americans and more than 10 million people worldwide live with Parkinsons. Replacing their lost dopamine neurons with reprogrammed brain cells could make management of their motor symptoms much easier, he notes. Instead of having to take eight pills or more every day in the later stages of the disease, people could reduce the amount of medication they have to take, maybe even down to zero.

But there are some caveats: Unfortunately, this is not going to halt the course of Parkinsons, Beck warns. If patients lose more dopamine neurons as the disease progresses, scientists or physicians may have to repeat the process of reprogramming replacement cells. And the disease often affects more than just dopamine neurons. There is a whole host of nonmotor symptoms that accompany Parkinsons, including cognitive impairment, depression, gastrointestinal complications and autonomic dysfunction. Motor improvement is only half the battle, according to Beck.

Researchers need to ensure the cocktail of added genes is standardized and produces robust cells in further tests. They will also need to verify that the process does not change other cells in the brain before it is ready for human clinical trials. Only a few small fetal and stem cell graft trials have been conducted so farand with mixed results, Beck said. But although this direct-reprogramming technique is being developed in parallel to stem cellbased therapies, it could be instructive as well as improve from clinical trials, eventually replacing stem cell therapy in the next decade, he adds. This is an insight into what the future of Parkinsons treatment holds.

Read this article:
Cell Therapy 2.0: Reprogramming the Brain's Own Cells for Parkinson's Treatment - Scientific American

Read More...

Stem Cell Basics IV. | stemcells.nih.gov

April 9th, 2017 6:44 pm

An adult stem cell is thought to be an undifferentiated cell, found among differentiated cells in a tissue or organ. The adult stem cell can renew itself and can differentiate to yield some or all of the major specialized cell types of the tissue or organ. The primary roles of adult stem cells in a living organism are to maintain and repair the tissue in which they are found. Scientists also use the term somatic stem cell instead of adult stem cell, where somatic refers to cells of the body (not the germ cells, sperm or eggs). Unlike embryonic stem cells, which are defined by their origin (cells from the preimplantation-stage embryo), the origin of adult stem cells in some mature tissues is still under investigation.

Research on adult stem cells has generated a great deal of excitement. Scientists have found adult stem cells in many more tissues than they once thought possible. This finding has led researchers and clinicians to ask whether adult stem cells could be used for transplants. In fact, adult hematopoietic, or blood-forming, stem cells from bone marrow have been used in transplants for more than 40 years. Scientists now have evidence that stem cells exist in the brain and the heart, two locations where adult stem cells were not at firstexpected to reside. If the differentiation of adult stem cells can be controlled in the laboratory, these cells may become the basis of transplantation-based therapies.

The history of research on adult stem cells began more than 60 years ago. In the 1950s, researchers discovered that the bone marrow contains at least two kinds of stem cells. One population, called hematopoietic stem cells, forms all the types of blood cells in the body. A second population, called bone marrow stromal stem cells (also called mesenchymal stem cells, or skeletal stem cells by some), were discovered a few years later. These non-hematopoietic stem cells make up a small proportion of the stromal cell population in the bone marrow and can generate bone, cartilage, and fat cells that support the formation of blood and fibrous connective tissue.

In the 1960s, scientists who were studying rats discovered two regions of the brain that contained dividing cells that ultimately become nerve cells. Despite these reports, most scientists believed that the adult brain could not generate new nerve cells. It was not until the 1990s that scientists agreed that the adult brain does contain stem cells that are able to generate the brain's three major cell typesastrocytes and oligodendrocytes, which are non-neuronal cells, and neurons, or nerve cells.

Adult stem cells have been identified in many organs and tissues, including brain, bone marrow, peripheral blood, blood vessels, skeletal muscle, skin, teeth, heart, gut, liver, ovarian epithelium, and testis. They are thought to reside in a specific area of each tissue (called a "stem cell niche"). In many tissues, current evidence suggests that some types of stem cells are pericytes, cells that compose the outermost layer of small blood vessels. Stem cells may remain quiescent (non-dividing) for long periods of time until they are activated by a normal need for more cells to maintain tissues, or by disease or tissue injury.

Typically, there is a very small number of stem cells in each tissue and, once removed from the body, their capacity to divide is limited, making generation of large quantities of stem cells difficult. Scientists in many laboratories are trying to find better ways to grow large quantities of adult stem cells in cell culture and to manipulate them to generate specific cell types so they can be used to treat injury or disease. Some examples of potential treatments include regenerating bone using cells derived from bone marrow stroma, developing insulin-producing cells for type1 diabetes, and repairing damaged heart muscle following a heart attack with cardiac muscle cells.

Scientists often use one or more of the following methods to identify adult stem cells: (1) label the cells in a living tissue with molecular markers and then determine the specialized cell types they generate; (2) remove the cells from a living animal, label them in cell culture, and transplant them back into another animal to determine whether the cells replace (or "repopulate") their tissue of origin.

Importantly, scientists must demonstrate that a single adult stem cell can generate a line of genetically identical cells that then gives rise to all the appropriate differentiated cell types of the tissue. To confirm experimentally that a putative adult stem cell is indeed a stem cell, scientists tend to show either that the cell can give rise to these genetically identical cells in culture, and/or that a purified population of these candidate stem cells can repopulate or reform the tissue after transplant into an animal.

As indicated above, scientists have reported that adult stem cells occur in many tissues and that they enter normal differentiation pathways to form the specialized cell types of the tissue in which they reside.

Normal differentiation pathways of adult stem cells. In a living animal, adult stem cells are available to divide for a long period, when needed, and can give rise to mature cell types that have characteristic shapes and specialized structures and functions of a particular tissue. The following are examples of differentiation pathways of adult stem cells (Figure 2) that have been demonstrated in vitro or in vivo.

Figure 2. Hematopoietic and stromal stem cell differentiation. Click here for larger image. ( 2008 Terese Winslow)

Transdifferentiation. A number of experiments have reported that certain adult stem cell types can differentiate into cell types seen in organs or tissues other than those expected from the cells' predicted lineage (i.e., brain stem cells that differentiate into blood cells or blood-forming cells that differentiate into cardiac muscle cells, and so forth). This reported phenomenon is called transdifferentiation.

Although isolated instances of transdifferentiation have been observed in some vertebrate species, whether this phenomenon actually occurs in humans is under debate by the scientific community. Instead of transdifferentiation, the observed instances may involve fusion of a donor cell with a recipient cell. Another possibility is that transplanted stem cells are secreting factors that encourage the recipient's own stem cells to begin the repair process. Even when transdifferentiation has been detected, only a very small percentage of cells undergo the process.

In a variation of transdifferentiation experiments, scientists have recently demonstrated that certain adult cell types can be "reprogrammed" into other cell types in vivo using a well-controlled process of genetic modification (see Section VI for a discussion of the principles of reprogramming). This strategy may offer a way to reprogram available cells into other cell types that have been lost or damaged due to disease. For example, one recent experiment shows how pancreatic beta cells, the insulin-producing cells that are lost or damaged in diabetes, could possibly be created by reprogramming other pancreatic cells. By "re-starting" expression of three critical beta cell genes in differentiated adult pancreatic exocrine cells, researchers were able to create beta cell-like cells that can secrete insulin. The reprogrammed cells were similar to beta cells in appearance, size, and shape; expressed genes characteristic of beta cells; and were able to partially restore blood sugar regulation in mice whose own beta cells had been chemically destroyed. While not transdifferentiation by definition, this method for reprogramming adult cells may be used as a model for directly reprogramming other adult cell types.

In addition to reprogramming cells to become a specific cell type, it is now possible to reprogram adult somatic cells to become like embryonic stem cells (induced pluripotent stem cells, iPSCs) through the introduction of embryonic genes. Thus, a source of cells can be generated that are specific to the donor, thereby increasing the chance of compatibility if such cells were to be used for tissue regeneration. However, like embryonic stem cells, determination of the methods by which iPSCs can be completely and reproducibly committed to appropriate cell lineages is still under investigation.

Many important questions about adult stem cells remain to be answered. They include:

Previous|IV. What are adult stem cells?|Next

More here:
Stem Cell Basics IV. | stemcells.nih.gov

Read More...

Lack Of Vision – Jewish Week

April 9th, 2017 6:44 pm

A wise man once noted that God gave human beings one mouth and two ears. You should prioritize accordingly, this sage concluded. The ratio of ears to eyes is less suggestive but Jewish lore has occasional hints that hearing might still be the preferred sense for gathering information. After all, when Divine Law was passed to the Children of Israel at Mount Sinai, it was done so orally, and the Israelites replied, We will do and we will hear.

These thoughts spring rather readily to mind when contemplating two new films, The Ticket and Karl Marx City, whose stories hinge on the unreliability of vision and the dangers of excessive vision, respectively. The first, a fiction film by Israeli writer-director Ido Fluk, examines the parabolic trajectory of a blind man who regains his sight, while the latter, a documentary by Petra Epperlein and Michael Tucker, investigates the undigested historical aftermath of the fall of the German Democratic Republic. While it might seem unlikely, the two films chime together.

James (Dan Stevens), the protagonist of The Ticket, lost his eyesight while in his teens. He has thrived despite that setback, and has a house, a wife, a son and apparent happiness, somewhere in the Midwest. When he wakes up one morning to find his vision restored the change energizes him. He goes from being an earnest, mildly successful real estate salesman in a firm that seems to specialize in hiring the blind to do cold calls, to reinventing himself as an unscrupulous predator, using the ongoing chaos of the post-crash market, combined with a slick line of fake self-help doctrines, to scam his neighbors out of their homes. At the same time, he trades up in car, house and wife, turning his back on the saintly Sam (Malin Akerman) for fellow wheeler-dealer Jessica (Kerry Bish) and dumping his best friend Bob (Oliver Platt).

Fluk and co-writer Sharon Mashihi clearly intend The Ticket as a parable and a cautionary tale about the fleeting nature of sensory pleasures. Fluk gives the film a substantial and creative layering of visual textures, particularly effective in the films opening moments when Jamess vision returns in a welter of flashes and movements of light, but he resists any urges to make the world in which the film is set concrete and specific. Consequently, The Ticket feels thin, moralistic without an anchor in a social reality.

Petra Epperlein in a scene from the documentary Karl Marx City, directed by Petra Epperlein and Michael Tucker. Photo courtesy of BOND/360.

That sensation is amplified by the rather flat characterizations. Jamess evolution from loving husband to louse needs more detail to make sense, a problem that is reinforced by the monotony of Stevenss performance (although his glassy blue-gray eyes, offset by a weak chin, make him an effective anti-hero reminiscent of Arthur Kennedy). With more psychological texture and concrete detail, The Ticket could have been a telling fable of incipient corruption. As it is, the film never is more than a blueprint for one.

Oddly, Karl Marx City is a brilliant reversal of that set-up, with the carefully chosen weight of details, drawn from hundreds of hours of surveillance footage and home movies, making the story of filmmaker Petra Epperlein and her family a potent stand-in for thousands whose lives were blighted by the paranoiac secret-keepers of the East German security state. The film takes its title from the East German name for what was once Chemnitz, Karl-Marx Stadt. Fittingly in the 1990s the industrial citys populace chose to return to the former name, trying to shuck off the GDR years as quickly as they had shed the Nazi period before them.

This is where Epperlein grew up and it was, the films narration rather tentatively proposes, a happy childhood. Her father was a successful management figure in one of the citys many industrial plants, esteemed by colleagues and superiors alike. When the Berlin Wall fell in 1989, he and his wife endured some economic hardships but nothing that would have suggested that shortly after New Years Day 1999, he would commit suicide. Epperleins investigation of the circumstances surrounding that event becomes the armature for her film, a stark and chilling accounting of the pervasive spy state that was the GDR.

Epperlein and Tucker astutely structure the film around a bricolage composed of Stasi footage and tapes, interviews with historians and curators specializing in the East German state, home movies and contemporary footage of Epperleins family and a series of recurring images of the co-director wandering the streets of Chemnitz with a boom mike in her hand, a somewhat obvious yet effective metaphor for her turning the tables on her nations former tormentors. All of this footage is either in black-and-white or faded period color until the penultimate shot of the film when the 21st century suddenly returns in the muted palette of a rather clinical-looking library, a moment made all the more effective for its subtle hues.

As we all know by now, the East German state was the perfect Orwellian beehive, with over 200,000 informers cooperating with the massive security apparatus to eavesdrop on a mere 17 million people. As Karl Marx City makes brutally clear, nothing was off limits in the states obsessive desire to know everything from their political attitudes to their personal hygiene, from their sexual preferences to what street they walked home on about its citizen-victims. And as any German Jew of a certain generation can tell you, that is not a safe street on which to walk home.

The Ticket is screening at the Cinema Village (22 E. 12th St.), and will be available on demand. Cinemavillage.com.

Karl Marx City is playing through April 11 at Film Forum (209 W. Houston St.). filmforum.org.

Original post:
Lack Of Vision - Jewish Week

Read More...

Still Waters: Renewed vision – Valley Courier

April 9th, 2017 6:44 pm

Give light to my eyes. Psalm 13:3.

Daddy has macular degeneration, the kind for which there is no cure, just worsening vision over time. It has taken most of the vision in one eye, and he just recently found out he has it in the other eye as well. However, the macular in that eye was masked by diminished vision from a cataract.

About a month ago the eye doctor finally decided the cataract was ripe enough to remove. The doctor said daddys eyesight in that eye could improve by 30 percent or more.

I had been praying for a long time that daddy would not completely lose his sight and that if there was something that could be done to improve it, it would be done. So I was glad for the prognosis of 30 percent 30 percent improvement in one eye is better than nothing.

The doctor removed the cataract but gave daddy the bad news that he had macular in that eye, too.

For now, though, his eyesight is better than it was (improved more than the predicted 30 percent), and the doctor is offering to perform another surgery that will help with some fluttering he has been experiencing. He has also regained enough sight to be able to drive again. He still has his license, and the surgery performed in March gave him distance vision. (He was always near sighted.) He isnt wearing glasses now except to read. He and my mother would like to take a drive up to their old haunts in Wyoming and Montana this summer or fall to celebrate their 65th wedding anniversary, and it would be nice if daddy could help with the driving (and not just as a side-seat driver.)

Daddy reads all the time, so it is important he can still see to keep up with the many magazines, newspapers and books he reads. He has to adjust to needing reading glasses while before he would take his glasses off to see up close.

I am grateful for even some improved vision for my father. I believe even though he doesnt have perfect vision, any improvement at this point is a miracle one of so many miracles that have guided and preserved my fathers life in all his 88 years (his birthday is today.)

He doesnt look or act anywhere near 88!

Even if his physical vision is impaired, my fathers spiritual eyesight is clear and becoming even more focused as he nears the destination he has been journeying toward for many decades now, the place where all that was cloudy and blurred will become plain and clear and he will see his Savior face to face.

Read the original here:
Still Waters: Renewed vision - Valley Courier

Read More...

Operation Sight Day leads 23 cataract patients back into the light – Salt Lake Tribune

April 9th, 2017 6:44 pm

Eight months later, Mahoney, 63, had the problem fixed at the University of Utah's John A. Moran Eye Center as part of a twice-yearly event known as Operation Sight Day, which provides free corrective surgery that typically costs $4,000 per eye to low-income patients. On Saturday, more than 30 U. medical staffers donated their time to treat 23 patients who would otherwise remain visually impaired.

The charity surgery program, which started in 2012, now includes the Eye Institute of Utah and the St. George Eye Center. Pharmaceutical companies donated the replacement lenses, and Bank of American Fork helped cover other costs.

Most people have cataracts forming on the lenses of their eyes, but for some, the process has sped up, clouding their vision and interfering with their life. Diet, sunlight, smoking, diabetes and even trauma can spur cataract formation.

"We all get them. You could be born with cataracts," said Alan Crandall, a professor of ophthalmology and Moran's director of glaucoma and cataract. He also spearheads global outreach for the center, leading and organizing humanitarian trips to Ghana for the past two decades and now other developing nations.

Cataracts can be more prevalent in equatorial regions because ultraviolet rays speed their formation. Without treatment available, many people are saddled with curable blindness, taking them and a caregiver, usually a younger family member, out of the workforce. In some communities, 30 percent of the people are either blind with cataracts or caring for someone with the condition, according to Crandall.

"When you cure the one person, you are returning two people back into the economy of that country; it's humongous," said Crandall, whose division also provides services on the Navajo Reservation. "We aren't a [medical] subspecialty, we are a necessity."

Crandall also has treated animals, such the dogs of homeless people, a kangaroo, a show-business tiger and Gorgeous, the Hogle Zoo's beloved gorilla who died of old age in 1999.

The surgery takes about 20 minutes and requires a local anesthetic. In the procedure, the eye is opened and an ultrasound is used to break up the clouded lens, which is sucked out. It is replaced with a clear acrylic foldable lens that will remain cataract free.

Unlike Mahoney, Maria Escojido doesn't recall when cataracts began ruining her eyesight. It started a long time ago and took years to blind her. Her right eye was treated at least year's Operation Sight Day, and she returned Saturday to repair the left one.

"I cannot drive at nighttime. It is hard to focus. We have a check from Social Security, but it's not enough," said Escojido. "I work like crazy my whole life with two jobs."

The 69-year-old house cleaner from Logan has 21 grandchildren and looks after her husband, Samuel, who has his own vision troubles, including glaucoma. After her surgery Saturday, she recovered with a protective cover over her left eye and relaxed with her husband at her side.

Mahoney, who is 63, said he was elated when he learned he was selected for the program. In a Moran consultation room, he covered his good eye and looked up at the ceiling light.

"I can barely tell there is a light. I can't see even see my hand," he said as he waved inches from his face. Now he looks forward to returning to work.

"I have a couple jobs lined up. I want to get back to work, but I don't want to get hurt," he said.

Originally posted here:
Operation Sight Day leads 23 cataract patients back into the light - Salt Lake Tribune

Read More...

Diabetes Epidemic In Mexico Is Fueled By Deep-Fried Tamales And … – NPR

April 9th, 2017 6:44 pm

A chile-rubbed pork taco is topped with french fries in the Merced market in Mexico City. The taco costs 10 pesos less than 50 cents. Cheap, high-calorie food is contributing to Mexico's obesity problem. Meghan Dhaliwal/for NPR hide caption

A chile-rubbed pork taco is topped with french fries in the Merced market in Mexico City. The taco costs 10 pesos less than 50 cents. Cheap, high-calorie food is contributing to Mexico's obesity problem.

Anais Martinez is on the hunt in Mexico City's Merced Market, a sprawling covered bazaar brimming with delicacies. "So this is the deep-fried tamale!" she says with delight, as if she'd just found a fine mushroom specimen deep in a forest.

The prized tamales are wrapped in corn husks and piled next to a bubbling cauldron of oil.

"It's just like a corn dough patty mixed with lard, put in a corn husk or banana leaf, steamed and then deep fried," says Martinez of this traditional Mexican breakfast. "And then after you fry it, you can put it inside a bun and make a torta [sandwich] out of it. So it's just like carbs and carbs and fat and fat. But it's actually really good."

And it only costs 10 pesos roughly 50 cents.

What's for breakfast? One Mexican option is a deep-fried tamale: a corn dough patty mixed with lard, wrapped in a corn husk or banana leaf and then put in a bun. Carbs upon carbs. Meghan Dhaliwal/for NPR hide caption

Martinez is a designer in Mexico City. She studied gastronomy here and now moonlights for a company called Eat Mexico giving street food tours.

Deeper in the market there's an area packed with taco stalls. Customers stand at the counters or sit on wobbly plastic stools. The young cooks fry, flip and chop various meats into tortillas. They pound strips of flank steak out on wooden cutting boards. Piles of red chorizo sausage simmer in shallow pools of oil. Yellow slabs of tripe hang from meat hooks.

We've just come to one of Martinez's favorite taco stands. Its specialty is pork tacos served with french fried potatoes piled on top.

Anais Martinez, a guide with Eat Mexico, leads tours of the sprawling Merced market in Mexico City, where stalls sell tacos, sandwiches and pastries. A huge meal can cost less than $2. Meghan Dhaliwal/for NPR hide caption

Anais Martinez, a guide with Eat Mexico, leads tours of the sprawling Merced market in Mexico City, where stalls sell tacos, sandwiches and pastries. A huge meal can cost less than $2.

"The pork is really thinly sliced, rubbed with chiles and spices and then they fry it," Martinez says as the meat sizzles on a long steel griddle in front of her. "Also, really good."

Rich, fatty street food like this is available all over Mexico at bus stops, at schools and on street corners. And it's affordable to the masses. A heaping plate of Martinez's favorite pork tacos costs less than a dollar.

All that cheap food in a country where incomes are rising is contributing to Mexico's massive diabetes epidemic.

Diabetes is now the leading cause of death in Mexico according to the World Health Organization. The disease takes an estimated 80,000 lives each year. Nearly 14 percent of adults in this country of 120 million suffer from the disease one of the highest rates of diabetes in the world. And it's all happened over the last few decades.

For roughly $2 a day, people in Mexico can now afford a diet heavy in carbohydrates, sugar and fat that delivers way more calories than the WHO's recommended daily intake of 2,000. A study in 2015 showed Mexico to be the leading consumer of junk food in Latin America, consuming 450 pounds of ultraprocessed foods and sugary beverages per person each year.

Rich, fatty street food is available all over Mexico. This vendor prepares tacos al pastor, with the meat cooked on a spit, outside a metro station in Mexico City. Meghan Dhaliwal/for NPR hide caption

Until just recently Mexico was the largest per capita consumer of soda in the world, chugging down 36 gallons of sugary drinks per person per year. That dubious distinction now falls to Argentina, with the U.S. and Chile not far behind.

Excessive body fat is one of the main contributors to the onset of Type 2 diabetes. And obesity rates have been climbing steadily in Mexico. It's now one of the world's most overweight countries, coming in just behind the United States.

Mexican health officials are well aware of the crisis. Late last year, the health minister declared diabetes and obesity to be public health emergencies the first time they'd made such a declaration that wasn't targeting an infectious disease.

"Diabetes is one of the biggest problems in the health system in Mexico," says Dr. Carlos Aguilar Salinas at the National Institute of Medical Sciences and Nutrition in Mexico City. "It's the first cause of death. It's the first cause of disability. It's the main cost for the health system."

Crowds pass a Coca-Cola store in Mexico City's Centro Historico district. In 2015, the average Mexican drank nearly two glasses of Coke a day. Meghan Dhaliwal/for NPR hide caption

Treating a patient with a severe case of diabetes in Mexico, he says, can cost upward of $40,000 a year. But the bigger problem, Aguilar says, is that the Mexican health system isn't prepared to treat the sheer number of diabetes patients with serious medical complications who show up in its clinics every day.

"The Mexican health system is very efficient to treat infectious disease," he says. But chronic disorders like diabetes, which require lifelong attention and medical monitoring, call for a different skill set from doctors. And Mexico's health system is still adjusting to this shift toward treating chronic disease.

Recognizing how daunting it is to treat diabetes, Mexican officials are trying to prevent it in the next generation. In 2014 the country slapped a controversial 5 cents per liter tax on soda. New rules bar advertisements for high calorie junk food aimed at children. Public service announcements encourage people to exercise more. And there's a major push to restrict the sale of soda and junk food in schools.

Gummy bears, potato chips and other snacks are sold on the sidewalk in downtown Mexico City. A study in 2015 ranked Mexico as the No. 1 consumer of junk food in Latin America: 450 pounds per person each year. Meghan Dhaliwal/for NPR hide caption

The head of the World Health Organization's office in Mexico, Dr. Gerry Eijkemans, says diabetes is a huge challenge to health care systems throughout Latin America.

"Diabetes used to be a disease of the rich," she says. "In Western Europe and the U.S., it was really the people who had the money who were obese, and now it's actually the opposite."

This is forcing already overstretched public health systems in Latin America to devote more resources to this complex disease.

"In order to prevent an infectious disease, you reduce the mosquitoes and basically you're done," Eijkemans says. "Not that it's easy, but it's much easier than changing a lifestyle, changing the way a society is basically organized [to encourage] people to consume unhealthy food with lots of fat and sugar."

An article earlier this year in the medical journal The Lancet warned: "Rising levels of increasingly severe obesity mean that, worldwide, populations are on the brink of a catastrophic epidemic of diabetes."

In Latin America, Mexico isn't on the brink of that epidemic, it's already there.

Continue reading here:
Diabetes Epidemic In Mexico Is Fueled By Deep-Fried Tamales And ... - NPR

Read More...

Obesity And Diabetes Kill More Than Initially Thought, According To … – Forbes

April 9th, 2017 6:44 pm

Forbes
Obesity And Diabetes Kill More Than Initially Thought, According To ...
Forbes
Here's a problem with death...besides it being death. The real cause of death is not always clear and obvious. Death certificates can be inaccurate. Case in point ...

and more »

See the rest here:
Obesity And Diabetes Kill More Than Initially Thought, According To ... - Forbes

Read More...

Erie teen with diabetes missing, at risk of having serious health … – The Denver Channel

April 9th, 2017 6:44 pm

High Wind Warningissued April 9 at 2:54PM MDT expiring April 10 at 12:00AM MDT in effect for: Larimer, Weld

Fire Weather Warningissued April 9 at 2:51PM MDT expiring April 9 at 6:00PM MDT in effect for: Weld

Freeze Warningissued April 9 at 2:43PM MDT expiring April 10 at 9:00AM MDT in effect for: Delta, Garfield, Gunnison, Mesa, Montrose

Wind Advisoryissued April 9 at 3:42AM MDT expiring April 9 at 6:00PM MDT in effect for: Delta, Garfield, Gunnison, Mesa, Montrose

Wind Advisoryissued April 9 at 3:42AM MDT expiring April 9 at 6:00PM MDT in effect for: Garfield, Gunnison, Mesa, Montrose

Wind Advisoryissued April 9 at 11:43AM MDT expiring April 9 at 6:00PM MDT in effect for: Garfield, Moffat, Rio Blanco, Routt

Fire Weather Warningissued April 9 at 2:25AM MDT expiring April 9 at 6:00PM MDT in effect for: Kit Carson, Yuma

Fire Weather Warningissued April 9 at 9:11AM MDT expiring April 9 at 6:00PM MDT in effect for: Cheyenne

High Wind Watchissued April 9 at 4:40AM MDT expiring April 10 at 3:00AM MDT in effect for: Boulder, Larimer, Weld

Fire Weather Warningissued April 9 at 4:00AM MDT expiring April 9 at 6:00PM MDT in effect for: Morgan, Washington

Fire Weather Warningissued April 9 at 4:00AM MDT expiring April 9 at 6:00PM MDT in effect for: Logan, Phillips, Sedgwick, Weld

Wind Advisoryissued April 9 at 2:51AM MDT expiring April 9 at 6:00PM MDT in effect for: Garfield, Moffat, Rio Blanco, Routt

Fire Weather Watchissued April 8 at 3:37PM MDT expiring April 9 at 6:00PM MDT in effect for: Logan, Phillips, Sedgwick, Weld

Freeze Watchissued April 8 at 10:41PM MDT expiring April 10 at 8:00AM MDT in effect for: Delta, Garfield, Gunnison, Mesa, Montrose

Go here to read the rest:
Erie teen with diabetes missing, at risk of having serious health ... - The Denver Channel

Read More...

Larry Hausner: A misguided proposal that sets Nevada back in fight against diabetes – Nevada Appeal

April 9th, 2017 6:44 pm

Diabetes is one of the most prevalent chronic diseases in Nevada. More than 12 percent of Nevadans have diabetes and, in 2012, diabetes was the seventh leading cause of death in the state. Legislative leaders could work to help address the diabetes epidemic in Nevada, yet some in Carson City are pursuing ill-advised policies. When I recently read SB 265, a state bill that aims to tackle drug costs for people with diabetes, it became quite clear to me our public officials, while well intentioned in their desire to help patients, don't realize what is truly driving the costs associated with the disease.

Caring for people with diabetes involves more than what they pay for insulin or another medication. In fact, most of the medical costs a person living with diabetes incurs has to do with other ailments, but having diabetes increases complexity of treatment and the costs of treatment with it. Also, diabetes seldom occurs alone. It's often accompanied by complications relating to high blood pressure, dyslipidemia, heart failure, kidney disease, and obesity. The complications relating to diabetes are the leading causes of lower limb amputations not relating to accidents or trauma and blindness.

Proponents of SB 265, led by some unions, casinos, and big health insurers, assert price controls will help lower drug costs for patients. That simply isn't the case. The proposal sets arbitrary price limits on certain diabetes medicines, with a focus on insulin, and requires drug makers to pay health insurance companies the difference. In fact, multiple witnesses at a recent hearing for the bill stated there's no guarantee patients will benefit. Even the bill's sponsor indicated there's much work yet to be done and the language is intentionally vague because it's unclear how the legislation might actually work. If this bill goes through, patients would pay the same for medications, insurers would increase their profits, and drug companies would have less reason and capital to invest in the innovative drugs for diabetes that are desperately needed. This is concerning.

The number of people diagnosed with diabetes has tripled in the last three decades. This increase means more patients need high-quality care, including different medication options, to help manage their disease. Innovative treatments, including oral medications and new forms of insulin, are absolutely critical. Unfortunately, SB 265 singles out diabetes patients, creates the high probability of access restrictions, and undermines their overall needs. With SB 265, patients would have fewer options when it comes to fully managing their disease and, as a result, every Nevadan would pay the price.

Instead of restricting access to care, Nevada should be exploring public policies that help us get in front of rising diabetes rates through prevention and actions to reduce the toll of diabetes on those already affected. This can be accomplished through greater access to innovative care, education and awareness initiatives, and bringing all stakeholders to the table to work together to reverse the growth in diabetes prevalence.

Patients must have information needed to choose the right insurance plan to help achieve positive results. Insulin research must continue to evolve, allowing patients superior control, less frequent injections, and better outcomes.

As a lifelong patient advocate, I know Nevadans expect more out of their elected officials.

Larry Hausner was chief executive officer of the American Diabetes Association from 2007 to 2014. He served as chief operating officer for The Leukemia & Lymphoma Society, and also worked for 15 years at the National Multiple Sclerosis Society. He currently serves on the Research America Board and Executive Committee and is chairman of the Campaign for Medical Discovery. In 2010, he received the Impact Award from the Invisible Disabilities Association for leading the charge in helping people living with diabetes through local and national education, research and support.

Link:
Larry Hausner: A misguided proposal that sets Nevada back in fight against diabetes - Nevada Appeal

Read More...

Dr. Monzor H. Yazji and Diana F. Ramirez | Special to The Monitor – Monitor

April 9th, 2017 6:44 pm

The way our bodies use sugar for growth and energy is part of metabolic disorder. There are three main types of diabetes: Type 1, Type 2 and gestational diabetes.

Normally, your body breaks down the sugars and carbohydrates you eat into a special sugar called glucose. Glucose fuels the cells in your body. But the cells need insulin, a hormone produced by pancreas, in your bloodstream in order to take in the glucose and use it for energy.

With diabetes mellitus, either your body doesnt make enough insulin, it cant use the insulin it does produce, or a combination of both (diabetes type 2). Insulin resistance from obesity in the setting of relative insulin deficiency contributes to the development of Type 2 diabetes. Type 2 diabetes mellitus accounts for most (90 percent to 95 percent) diagnosed cases. Prevalence: In 2012, 29.1 million Americans, or 9.3 percent of the population, had diabetes. Approximately 1.25 million American children and adults have Type 1 diabetes ( ADA. Asian Americans, American Indians, Alaska Natives, Hispanics, and non Hispanic black persons are at an increased risk for developing diabetes compared with non Hispanic white persons.

The Hispanic population is the fastest growing segment in the United States, and it has one of the highest rates of diabetes. The estimated diabetes prevalence rate in the Rio Grande Valley is over 30 percent. But I believe is much higher especially with undiagnosed ones. Since the cells cant take in the glucose, it builds up in your blood. High levels of blood glucose can damage the tiny blood vessels in your kidneys, heart, eyes, or nervous system. Thats why diabetes especially if left untreated can eventually cause heart disease, stroke, kidney disease, blindness, and nerve damage to nerves in the feet.

The warning signs of diabetes can be so mild that you dont notice them. Type 2 diabetes generally has an insidious onset of prolonged asymptomatic hyperglycemia. Most patients do not present with the classic symptoms of polydipsia (very thirsty,or polyuria (urinating a lot). With Type 1 diabetes, the symptoms usually happen quickly, in a matter of days or a few weeks. Some of the warning symptoms are getting very tired, unplanned weight loss, feeling very hungry, blurry vision, recurrent infections and prolonged wound healing. One of every four people with diabetes doesnt know they have it. See if your risk of having the disease is high (family history of diabetes, overweight or obese (Body Mass Index greater than 25), large waist circumference (women greater than 35 inches/ men greater than 40 inches), dark skin at the neck, having similar symptoms, etc.) ask your doctor to check you.

A blood glucose test measures the amount of a type of sugar, called glucose, in your blood. Glucose comes from carbohydrate foods. It is the main source of energy used by the body. The hemoglobin A1c test, also called HbA1c, glycated hemoglobin test, or glycohemoglobin, is an important blood test that shows how well your diabetes is being controlled. Some serious health issues linked to diabetes may not have any symptoms, such as: kidney disease, high blood pressure and heart disease.

With diabetes, you may not have symptoms of heart disease even if youre having a heart attack. And if you have kidney disease, there could be no warning signs until your kidneys are damaged. Bariatric surgeries could heal diabetes mellitus Type 2 if the BMI over 35 with two risk factors or over 40. My recommendation to diabetic patient or whom have risks: See your doctor every three months and ask him/her to educate you and share with you the care plan (team work).

Try to lose weight if youre overweight (BMI >25). Eat healthy (Mediterranean diet is a good one) and dont skip meals (three meals with snack before bed time). Exercise regularly (minimum 250 minutes/week). Take your diabetes medication as prescribed. If you smoke, get help to quit. Work with your doctor to keep your blood sugar, blood pressure, and cholesterol under control.

The Rio Grande Valley Diabetes Association is a local non-profit organization whose mission is dedicated to the prevention of diabetes and its complications through educational services, early detection and awareness. The RGVDAs focus is to bring attention on a growing health epidemic that affects one out of every four people in Hidalgo Country, making it one of the worst afflicted areas in the country. Type 2 diabetes is preventable and also manageable through a healthy regimen of exercise and dieting, The RGVDA offers free monthly cooking.

The Rio Grande Valley Diabetes Association (RGVDA) provides The Monitor a monthly article to educate the public about the prevention and control of diabetes through monthly articles.

Read the original post:
Dr. Monzor H. Yazji and Diana F. Ramirez | Special to The Monitor - Monitor

Read More...

Saving Baby Teeth May Be Beneficial – Opposing Views

April 9th, 2017 6:44 pm

Opposing Views
Saving Baby Teeth May Be Beneficial
Opposing Views
Cellular medicine is going to be a big part of what we rely on to rebuild broken parts of the body, said Dr. Joe Laning, the chief technology officer at Store-A-Tooth (a lab that stores stem cells from baby teeth), according to Global News ...

Go here to see the original:
Saving Baby Teeth May Be Beneficial - Opposing Views

Read More...

Pioneering work on stem-cell therapies at UW deserves state support – Seattle Times

April 9th, 2017 6:43 pm

At the University of Washingtons Institute for Stem Cell and Regenerative Medicine, scientists and physicians are manipulating stem cells to heal and restore the function of hearts, eyes, kidneys and other tissues.

IF you have a heart attack, hopefully youll survive. But your body will be forever changed. The worlds best doctors cant undo the damage; instead, drugs and devices will help you live with a heart whose function too often dwindles.

The body cannot replace muscle cells that die in heart attacks maladies that help make heart failure the No. 1 global cause of death and our nations biggest health care expense. These patients face daily medication, decreased energy and, for the lucky 0.1 percent, the ability to qualify for an extraordinarily costly heart transplant and anti-rejection medication that also leaves them more vulnerable to other diseases.

Thanks to medical advances, heart failure has become a chronic condition that people are now managing for decades. The same is true for diabetes, kidney disease and arthritis. But with that longevity comes a tether to drug regimens whose costs rise seemingly at whim.

Dr. Charles Murry is interim director of UW Medicines Institute for Stem Cell and Regenerative Medicine.

These chronic diseases are a major reason that health-care costs hold center stage in Americans consciousness.

Amid our collective uncertainty, medical science offers one path of relief. Specifically, the engineering of human cells and tissues to restore vitality to poorly functioning organs.

The medical conditions named above share a common root not addressed by todays best care: The body is missing a population of cells that do critical work. If we could restore that population, we could cure many chronic diseases.

At the University of Washingtons Institute for Stem Cell and Regenerative Medicine (ISCRM), scientists and physicians are manipulating stem cells to heal and restore the function of hearts, eyes, kidneys and other tissues.

This year, we also seek a first-time investment from our state Legislature.

Weve pioneered techniques to grow unlimited human heart muscle cells in the lab. We were the first to transplant these cells into injured hearts and repair the injury with new tissue growth. UW Medicine will begin first-in-human tests of these cells in Seattle in 2019.

If this one and done treatment prevents heart failure in even the sickest 10 percent of heart-attack patients, our nation could save a staggering $3.5 billion per year in health-care costs. More importantly, these patients will lead longer, healthier, more productive lives.

Other ISCRM scientists are pursuing a gene therapy for muscular dystrophy, a devastating illness that often strikes young boys. The therapy, tested in Labrador puppies that were paraplegic as a result of the same, naturally occurring muscle-wasting disease, had the dogs leaping and frolicking in just weeks. A clinical trial is planned for 2018.

We are similarly probing therapies for cancer, kidney failure, diabetes and Alzheimers. And were doing this with the Northwests entrepreneurial spirit: In the past decade, ISCRM has patented 250+ discoveries with commercial potential and started 20 companies.

Legislatures in at least 11 other states, including California, New York, Wisconsin, Minnesota and Maryland, have invested cumulative billions in regenerative medicine. Most of that funding has gone to university-based research centers like ours.

To this point there has been no state investment in ISCRM. Nevertheless we have built a world-class program with federal grants and private philanthropy. But those dollars come in boom-and-bust cycles, and what we need now is stable funding to maintain competitiveness.

For this reason, the UW seeks $6 million in operating funds from the Legislature, starting with the next biennium, to recruit and retain top scientists, fund promising results at early stages, and train young researchers and clinicians.

We are grateful, at this juncture, that the state Senate included us in its initial budget.

We ask all legislators to invest in the health of our residents and in the promise of what weve accomplished so far. With stem-cell biology, we are ready to rebuild solid tissues like the heart and potentially cure our nations greatest cause of death and health-care expense.

Clinical success will make Washington a destination for heart repair and other regenerative therapies. This race is ours to lose.

Read more from the original source:
Pioneering work on stem-cell therapies at UW deserves state support - Seattle Times

Read More...

Page 1,035«..1020..1,0341,0351,0361,037..1,0401,050..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick